Navigation Links
Yongye Biotechnology to Present at Roth Capital 'China Comes to Vegas' Conference
Date:11/10/2008

BEIJING, Nov. 10 /Xinhua-PRNewswire-FirstCall/ -- Yongye Biotechnology International, Inc. (OTC Bulletin Board: YGYB; "Yongye" or the "Company"), a leading developer, producer and distributor of nutrients for plants and animals, located in the People's Republic of China, today announced that the Company will present at the upcoming Roth Capital "China Comes to Vegas" conference held on November 19-21, 2008 at the Wynn Hotel in Las Vegas, Nevada.

The Roth Capital "China Comes to Vegas" conference is a three day event dedicated to US listed companies with operations in China. There will be executives from more than 70 companies at the conference. Details of Yongye's presentation are:

Date: Friday, November 21, 2008

Time: 01:00 P.M. Pacific Time

Presenters: Mr. Zishen Wu, Chairman and CEO;

Mr. Larry Gilmore, Vice President of Corporate Strategy

Venue: Palmer 1

Wynn Hotel

Las Vegas, Nevada

The Company will be available to meet with analysts and investors during the conference. Participation in the Roth "China Comes to Vegas" conference is by invitation only. For more information about the conference, please visit http://www.roth.com/ or E-mail conference@roth.com .

About Yongye Biotechnology International, Inc.

Yongye Biotechnology International, Inc., headquartered in Beijing, is engaged in the research and development, distribution and sales of fulvic acid based nutrients for plants and animals. The Company's patent pending processes and proprietary formulas allow it to create products that increase crop yields and improve the health of livestock. Its sole operating subsidiary, Yongye Nongfeng Biotechnology Company, Ltd., is located in Inner Mongolia, People's Republic of China. The Company sells its products through distributors and directly to farmers located in ten provinces throughout China.

Safe Harbor Statement

This press release contains certain statements that may include "forward looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on the SEC's website ( http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For more information, please contact:

Yongye Biotechnology International, Inc.

Mr. Larry Gilmore-VP of Corporate Strategy

Phone: +86-8232-8866 x8880

Email: larry.gilmore@gmail.com

CCG Investor Relations, Inc.

Mr. Crocker Coulson, President

Phone: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com

Web: http://www.ccgirasia.com


'/>"/>
SOURCE Yongye Biotechnology International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
2. Yongye Biotechnology International Raises $9.4 Million in Private Placement
3. Yongye Biotechnology International Announces Second Quarter Results
4. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
5. Yongye Biotechnology International Retains CCG Investor Relations
6. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
7. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
8. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
9. InNexus Biotechnology Receives Patent Grants in Europe
10. InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum
11. TechConnect World 2009 Matches Tomorrows Technology Solutions with Todays Business Needs for Clean-Technology, Biotechnology and Nanotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... ... Doctors in Italy, Japan, the UK and the US have reached some surprising ... its link to malignant mesothelioma. Surviving Mesothelioma has just posted the details of their ... , The studies analyzed for the new report included more than 3,447 cancer patients. ...
(Date:5/26/2016)... NEW YORK , May 26, 2016 ... announced today that it will be a featured presenter at ... 2016 in New York City at ... Denis Corin , Q BioMed Inc. CEO, is scheduled ... presentation will cover the company,s business strategy, recent developments and ...
(Date:5/25/2016)... ... May 25, 2016 , ... Lajollacooks4u has become a rising hotspot ... rated one of its top attractions. Fortune 500 companies, such as Illumina, Hewlett-Packard, ... unique and intimate team-building experience. , Each event kicks off with an olive oil ...
(Date:5/25/2016)... , ... May 25, 2016 , ... Scientists at the ... options being tried for mesothelioma may be hampering the research that could lead to ... Click here to read it now. , The team evaluated 98 ...
Breaking Biology Technology:
(Date:3/14/2016)... , Allemagne, March 14, 2016 ... ) - --> - Renvoi : image ... --> --> ... biométriques, fournit de nouveaux lecteurs d,empreintes digitales pour ... de DERMALOG sera utilisé pour produire des cartes ...
(Date:3/10/2016)... 10, 2016   Unisys Corporation (NYSE: UIS ... (CBP) is testing its biometric identity solution at the ... to help identify certain non-U.S. citizens leaving the country. ... designed to help determine the efficiency and accuracy of using ... and will run until May 2016. --> ...
(Date:3/8/2016)... March 8, 2016   Valencell , the ... announced it has secured $11M in Series D ... a new venture fund being launched by UAE-based ... from existing investors TDF Ventures and WSJ Joshua ... continue its triple-digit growth and accelerate its pioneering ...
Breaking Biology News(10 mins):